TICKERNERD
Menu
CNTXCNTXHealthcare · Biotechnology

CNTX Stock Forecast: Context Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.35
−4.26% on the day

The 10 Wall Street analysts covering Context Therapeutics, Inc. hold a median 12-month price target of $5 — +1326.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 11 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$32.2M
Ticker Nerd rank
28 / 100
Median analyst target
$5.00
Analysts covering
10
Revenue$0.0
Operating income−$15.0M
Net income−$14.6M
Free cash flow−$11.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.5%
1M
−24.8%
YTD
−76.2%
1Y
−58.1%
From 52W high
−89.6%
From 52W low
0.0%
$0.35
$3.36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CNTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Context Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
85
Volatility
73
Accruals
72
Quality
53
Issuance
31
Revisions
29
Growth
25
Value
19
Momentum
17

Size (85): Smaller than most of the companies we track.

Momentum (17): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CNTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26CNTXHigh $6.00Median $5.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $2.00Median $5.00High $6.00

The green dot is the last close — the median target sits +1326.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 June 2026Maxim GroupMaintainsBuy$8.00 → $4.00
16 June 2026Maxim GroupMaintainsBuy—
24 Mar 2026D. Boral CapitalMaintainsBuy—
24 Mar 2026GuggenheimReiteratesBuy—
24 Mar 2026Piper SandlerMaintainsOverweight—
22 Dec 2025Jones TradingInitiatesBuy—
6 Nov 2025D. Boral CapitalMaintainsBuy—
6 Nov 2025HC Wainwright & Co.MaintainsBuy—
16 Oct 2025D. Boral CapitalMaintainsBuy—
2 Oct 2025Cantor FitzgeraldInitiatesOverweight—
18 Sept 2025GuggenheimInitiatesBuy—
7 Aug 2025D. Boral CapitalMaintainsBuy—
7 Aug 2025HC Wainwright & Co.MaintainsBuy—
26 June 2025Piper SandlerReiteratesOverweight—
8 May 2025D. Boral CapitalMaintainsBuy—
29 Apr 2025D. Boral CapitalMaintainsBuy—
21 Apr 2025William BlairInitiatesOutperform—
9 Apr 2025D. Boral CapitalMaintainsBuy—
21 Mar 2025D. Boral CapitalMaintainsBuy—
21 Mar 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CNTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CNTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Context Therapeutics, Inc. returned −58.1% against +17.5% for the S&P 500, dividends included.

CNTX vs S&P 500, last 12 monthsTotal return, rebased to 100
0100200300400Oct 25Jan 26Apr 26Jul 26CNTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CNTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
6
Fundamentals

Context Therapeutics, Inc. (CNTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.9×

Cheaper than 82% of US stocks

Price / sales
—
Price / book
0.8×

Cheaper than 78% of US stocks

EV / EBITDA
0.2×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−76.1%

Higher than 16% of US stocks

Return on assets
−45.7%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Context Therapeutics, Inc. (CNTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Context Therapeutics, Inc. has a market value of $32.2M and an enterprise value of −$10.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$46.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$40.5M.

  • Shares outstanding: 91.9M.

  • Trailing P/E: −0.9×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Context Therapeutics, Inc. employs 15 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

CNTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CNTXContext Therapeutics, Inc.$32.2M
28
KYNBKyntra Bio, Inc.$32.3M
45
ALGSAligos Therapeutics, Inc.$32.3M
74
NXTCNextCure, Inc.$32.0M
80
LGVNLongeveron, Inc.$32.9M
30
BYSIBeyondSpring, Inc.$31.4M
19
BCTXBriaCell Therapeutics Corp.$31.3M
7

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Context Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CNTX news & analysis

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

GlobeNewsWire · 9 Sept 2026positive

Context Therapeutics announced that the first patient has been dosed in the Phase 1 clinical trial of CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody being evaluated as a monotherapy in patients with urothelial, colorectal, and triple-negative breast cancers.

Why it matters — This milestone advances Context's lead TCE bispecific antibody program toward clinical data, marking progress in its pipeline for solid tumors.

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

GlobeNewsWire · 5 Aug 2026neutral

Context Therapeutics reported its financial results for the second quarter ended June 30, 2026, and provided a pipeline update, including the prioritization of its CTIM-76 and CT-202 clinical programs with initial clinical readouts expected beginning in Q2 2027. The company also highlighted interim Phase 1a data from CTIM-76 in a limited number of heavily pretreated patients with platinum-resistant ovarian cancer receiving weekly dosing, and reported $43.0 million in cash and cash equivalents as of June 30, 2026, expected to fund operations into Q4 2027.

Why it matters — A CNTX watcher would track this update for the company's program prioritization, upcoming clinical readouts, and its cash runway extending into Q4 2027, which bears on how the pipeline can be advanced.

FAQ

Frequently asked questions about CNTX stock

What is the CNTX stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Context Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $2 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CNTX stock a buy right now?

Of the 10 analysts covering Context Therapeutics, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Context Therapeutics, Inc. 28 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CNTX?

As at 11 Sept 2026, Context Therapeutics, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).

Will CNTX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +1326.9% from the last close, and Ticker Nerd's factor model ranks Context Therapeutics, Inc. 28 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CNTX stock forecast for 2030?

No analyst covering Context Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $6 over the next 12 months.

How has CNTX stock performed over the past year?

Context Therapeutics, Inc. returned -58.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Context Therapeutics, Inc. do?

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for solid tumors, with an emphasis on hormone-driven breast and gynecological cancers.

What is the latest news on CNTX?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202". Context Therapeutics announced that the first patient has been dosed in the Phase 1 clinical trial of CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody being evaluated as a monotherapy in patients with urothelial, colorectal, and triple-negative breast cancers.

Company

About Context Therapeutics, Inc.

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for solid tumors, with an emphasis on hormone-driven breast and gynecological cancers. Its current pipeline centers on T cell engaging bispecific antibodies designed to direct immune activity toward cancer cells, including programs targeting CLDN6, mesothelin, and Nectin-4. The company is advancing these candidates through early-stage clinical and preclinical development, with particular attention to cancers such as ovarian, endometrial, and breast cancer. Context Therapeutics Inc. operates as an oncology-focused biotechnology company and works to translate targeted immunotherapy research into potential treatments for genetically and biologically defined patient populations. Headquartered in Philadelphia, Pennsylvania, it remains centered on drug discovery and clinical development rather than commercialized products.

CEO Mr. Martin A. Lehr · 15 employees · United States · https://www.contexttherapeutics.com